Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evofosfamide - Molecular Templates

Drug Profile

Evofosfamide - Molecular Templates

Alternative Names: HAP 302; TH-302; TH302-cpd

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Threshold Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Developer Grupo Espanol de Tumores Neuroendocrinos; Merck KGaA; Molecular Templates; Threshold Pharmaceuticals; University of Texas Health Science Center at San Antonio; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Nitroimidazoles; Phosphoramide mustards; Small molecules
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Biliary cancer; Glioblastoma
  • Suspended Leukaemia; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Solid tumours
  • Discontinued Soft tissue sarcoma

Most Recent Events

  • 28 Dec 2022 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 31 May 2022 Immunogenesis enters into a collaboration agreement with Agenus to support a clinical trial evaluating the combination of balstilimab, zalifrelimab with evofosfamide for treatment of Solid tumours
  • 31 May 2022 Agenus in collaboration with Immunogenesis plans a clinical trial for Solid tumours (Combination therapy, Late-stage disease)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top